Solid lipid nanoparticles (SLN™)

Fundamentals of Pharmaceutical Nanoscience

Volumn , Issue , 2013, Pages 91-116

  Souto, Eliana B ^a,b   Fangueiro, Joana F ^b   Müller, Rainer H ^c  

^a UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^b UNIVERSIDADE FERNANDO PESSOA   (Portugal)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACIDS; NANOPARTICLES; PARTICLE SIZE; TARGETED DRUG DELIVERY;

CLINICAL USE; DRUG DELIVERY SYSTEM; IN-VITRO; KEYPOINTS; NANOTOXICOLOGY; PHYSICO-CHEMICAL CHARACTERIZATION; SOLID LIPID NANOPARTICLE (SLN); STRUCTURAL PARAMETER;

CONTROLLED DRUG DELIVERY;

EID: 84916209213     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-9164-4_5     Document Type: Chapter

References (137)

1. Aditya NP et al (2010) Arthemeter-loaded lipid nanoparticles produced by modified thin-film hydration: pharmacokinetics, toxicological and in vivo anti-malarial activity. Eur J Pharm Sci 40(5):448–455
2. Aji Alex MR et al (2011) Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur J Pharm Sci 42(1–2):11–18
3. Almeida AJ, Souto E (2007) Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev 59(6):478–490
4. Almeida AJ, Runge S, Müller RH (1997) Peptide-loaded solid lipid nanoparticles (SLN): influence of production parameters. Int J Pharm 149(2):255–265
5. Ann PD (2004) Development of nanotechnologies. Mater Today 7(12 suppl):30–35
6. Araújo J et al (2009) Nanomedicines for ocular NSAIDs: safety on drug delivery. Nanomed Nanotechnol Biol Med 5(4):394–401
7. Attama AA, Müller-Goymann CC (2008) Effect of beeswax modification on the lipid matrix and solid lipid nanoparticle crystallinity. Colloids Surf, A Physicochem Eng Asp 315(1–3):189–195
8. Attama AA, Reichl S, Muller-Goymann CC (2009) Sustained release and permeation of timolol from surface-modified solid lipid nanoparticles through bioengineered human cornea. Curr Eye Res 34:698–705
9. Barber TA (1993) Pharmaceutical particulate matter: analysis and control. Interpharm Press, Buffalo Grove, IL
10. Başaran E et al (2010) Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery. J Microencapsul 27(1):37–47
11. Battaglia L, Gallarate M (2012) Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery. Exp Opin Drug Deliv 9:497–508
12. Battaglia L et al (2010) Solid lipid nanoparticles produced through a coacervation method. J Microencapsul 27(1):78–85
13. Berne BJ, Pecora R (2000) Dynamic light scattering: with applications to chemistry, biology, and physics. Wiley, Mineola
14. Bhargava R, Levin IW (2001) Fourier transform infrared imaging: theory and practice. Anal Chem 73:5157–5167
15. Blasi P et al (2007) Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev 59(6):454–477
16. Blasi P et al (2011) Lipid nanoparticles for brain targeting I. Formulation optimization. Int J Pharm 419(1–2):287–295
17. Bunjes H (2005) Characterization of solid lipid nano- and microparticles. In: Nastruzzi C (ed) Lipospheres in drug targets and delivery. CRC Press, Florida
18. Bunjes H, Unruh T (2007) Characterization of lipid nanoparticles by differential scanning calorimetry, X-ray and neutron scattering. Adv Drug Deliv Rev 59(6):379–402
19. Bunjes H, Koch MHJ, Westesen K (2003) Influence of emulsifiers on the crystallization of solid lipid nanoparticles. J Pharm Sci 92(7):1509–1520
20. Carbone C et al (2012) Preparation and optimization of PIT solid lipid nanoparticles via statistical factorial design. Eur J Med Chem 49:110–117
21. Cavadas M, González-Fernández Á, Franco R (2011) Pathogen-mimetic stealth nanocarriers for drug delivery: a future possibility. Nanomed Nanotechnol Biol Med 7(6):730–743
22. Cavalli R et al (2002) Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm 238(1–2):241–245
23. Cengiz E et al (2006) Sunblocking efficiency of various TiO(2)-loaded solid lipid nanoparticle formulations(1). Int J Cosmet Sci 28(5):371–378
24. Christian GD, O’Reilly JE (1986) Instrumental analysis, 2nd edn. Allyn and Bacon, Boston
25. Corrias F, Lai F (2011) New methods for lipid nanoparticles preparation. Recent Pat Drug Deliv Formul 5(3):212–213
26. Coutts-Lendon CA et al (2003) The use of FT-IR imaging as an analytical tool for the characterization of drug delivery systems. J Control Release 93(3):223–248
27. Cui Z, Qiu F, Sloat BR (2006) Lecithin-based cationic nanoparticles as a potential DNA delivery system. Int J Pharm 313(1–2):206–213
28. Das S et al (2011) Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables. Colloids Surf B: Biointerfaces 88(1):483–489
29. del Pozo-Rodríguez A et al (2008) Solid lipid nanoparticles for retinal gene therapy: transfection and intracellular trafficking in RPE cells. Int J Pharm 360(1–2):177–183
30. del Pozo-Rodríguez A et al (2010) Solid lipid nanoparticles as potential tools for gene therapy: in vivo protein expression after intravenous administration. Int J Pharm 385(1–2):157–162
31. Dhont JKG (2001) An Introduction to Dynamics of Colloids Volume 2 in: Colloid and Surface Chemistry- Studies in Interface Science, Möbius D, Miller R (eds). Elsevier Science B. V. Amsterdam Doktorovova S et al (2010) Formulating fluticasone propionate in novel PEG-containing nanostructured lipid carriers (PEG-NLC). Colloids Surf B: Biointerfaces 75(2):538–542
32. Doktorovova S et al (2011) Cationic solid lipid nanoparticles (cSLN): structure, stability and DNA binding capacity correlation studies. Int J Pharm 420(2):341–349
33. Doktorovova S et al (2012) Modified Rose Bengal assay for surface hydrophobicity evaluation of cationic solid lipid nanoparticles (cSLN). Eur J Pharm Sci 45:606–612
34. Dong X, Mumper RJ (2006) The metabolism of fatty alcohols in lipid nanoparticles by alcohol dehydrogenase. Drug Dev Ind Pharm 32(8):973–980
35. Dong Y et al (2012) Solid lipid nanoparticles: continuous and potential large-scale nanoprecipitation production in static mixers. Colloids Surf B: Biointerfaces 94:68–72
36. Dowling A et al (2004) Nanoscience and nanotechnologies: opportunities and uncertainties. The Royal Society and the Royal Academy of Engineering, London
37. Dreher F et al (1997) Interaction of a lecithin microemulsion gel with human stratum corneum and its effect on transdermal transport. J Control Release 45(2):131–140
38. Dubes A et al (2003) Scanning electron microscopy and atomic force microscopy imaging of solid lipid nanoparticles derived from amphiphilic cyclodextrins. Eur J Pharm Biopharm 55(3):279–282
39. Eshel G et al (1991) Critical evaluation of the use of laser diffraction for particle-size distribution analysis. Soil Sci Soc Am J 68(3):736–743
40. Fangueiro J et al (2012) Thermodynamic behaviour of lipid nanoparticles upon delivery of vitamin E derivatives into the skin: in vitro studies. J Thermal Analysis Calorim 108:275–282
41. Fangueiro JF et al (2013) A novel lipid nanocarrier for insulin delivery: production, characterization and toxicity testing. Pharm Dev Technol 18:545–549
42. Souza, A.L. et al (2012) Loading of praziquantel in the crystal lattice of solid lipid nanoparticles: Studies by DSC and SAXS. J Thermal Analysis Calorim 108:353–360
43. Filion MC, Phillips NC (1997) Anti-inflammatory activity of cationic lipids. Br J Pharmacol 122(3):551–557
44. Fontana G et al (2005) Preparation, characterization and in vitro antitumoral activity of solid lipid nanoparticles (SLN) containing tamoxifen. Drug Deliv 12(6):385–392
45. Ford JL, Mann TE (2012) Fast-Scan DSC and its role in pharmaceutical physical form characterization and selection. Adv Drug Deliv Rev 64:422–430
46. Friedrich H et al (2010) Imaging of self-assembled structures: interpretation of TEM and cryo-TEM images. Angew Chem Int 49:7850–7858
47. Garcia-Fuentes M, Torres MR, Alonso JM (2002) Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules. Colloids Surf B: Biointerfaces 27:159–168
48. Gasco MR (1997) Solid lipid nanospheres from warm microemulsion. Pharm Tech Eur 9:52–58
49. Geisse NA (2009) AFM and combined optical techniques. Mater Today 12(7–8):40–45
50. Gethner JS, Gaskin F (1978) Dynamic light scattering from solutions of microtubules. Biophys J 24:505–515
51. Ghadiri M et al (2012) Loading hydrophilic drug in solid lipid media as nanoparticles: statistical modeling of entrapment efficiency and particle size. Int J Pharm 424(1–2):128–137
52. Gill P, Moghadam TT, Ranjbar B (2010) Differential scanning calorimetry techniques: applications in biology and nanoscience. J Biomol Tech 21(4):167–193
53. Gokce EH et al (2008) Cyclosporine a loaded SLNs: evaluation of cellular uptake and corneal cytotoxicity. Int J Pharm 364(1):76–86
54. Harms M, Müller-Goymann CC (2011) Solid lipid nanoparticles for drug delivery. J Drug Del Sci Tech 21(1):89–99
55. Heike B (2011) Structural properties of solid lipid based colloidal drug delivery systems. Curr Opin Colloid Interface Sci 16(5):405–411
56. Heurtault B et al (2002) A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm Res 19(6):875–880
57. Heurtault B et al (2003) Physico-chemical stability of colloidal lipid particles. Biomaterials 24(23):4283–4300
58. Hiemenz PC, Rajagopalan R (1997) Principles of colloid and surface chemistry, 3rd edn. Marcel Dekker, New York
59. Hu FQ et al (2002) Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization. Int J Pharm 239(1–2):121–128
60. Jenknins R (2000) X-ray techniques: overview. In: Meyers RA (ed) Encyclopedia of analytical chemistry. Wiley, Chichester, pp 1–20
61. Jenning V, Gohla S (2000) Comparison of wax and glyceride solid lipid nanoparticles (SLN®). Int J Pharm 196(2):219–222
62. Kalam MA et al (2010) Preparation, characterization, and evaluation of gatifloxacin loaded solid lipid nanoparticles as colloidal ocular drug delivery system. J Drug Target 18(3):191–204
63. Kaneko F (2001) Polymorphism and phase transitions of fatty acids and acylglycerols. In: Garti N, Sato K (eds) Crystallization processes in fats and lipid systems. Marcel Dekker, New York, pp 53–98
64. Kheradmandnia S et al (2010) Preparation and characterization of ketoprofen-loaded solid lipid nanoparticles made from beeswax and carnauba wax. Nanomed Nanotechnol Biol Med 6(6):753–759
65. Kim B-D, Na K, Choi H-K (2005) Preparation and characterization of solid lipid nanoparticles (SLN) made of cacao butter and curdlan. Eur J Pharm Sci 24(2–3):199–205
66. Krakty O (1982) Part I- A Survey in Small Angle X-Ray Scattering, Glatter O, Krakty O (eds). Academic Press Inc., London p 3–15
67. Kuntsche J, Horst JC, Bunjes H (2011) Cryogenic transmission electron microscopy (cryo-TEM) for studying the morphology of colloidal drug delivery systems. Int J Pharm 417:120–137
68. Kuo Y-C, Chen H-H (2009) Entrapment and release of saquinavir using novel cationic solid lipid nanoparticles. Int J Pharm 365(1–2):206–213
69. Kuo Y-C, Chung C-Y (2011) Solid lipid nanoparticles comprising internal Compritol 888 ATO, tripalmitin and cacao butter for encapsulating and releasing stavudine, delavirdine and saquinavir. Colloids Surf B: Biointerfaces 88(2):682–690
70. Kuo Y-C, Lin C-W (2009) Effect of electromagnetic field and surface modification on the electrical behavior of novel solid lipid nanoparticles covered with l-arginine. Colloids Surf B: Biointerfaces 71(1):45–51
71. Kuo Y-C, Wang C-C (2010) Electrophoresis of human brain microvascular endothelial cells with uptake of cationic solid lipid nanoparticles: effect of surfactant composition. Colloids Surf B: Biointerfaces 76(1):286–291
72. Liu J et al (2008) Solid lipid nanoparticles for pulmonary delivery of insulin. Int J Pharm 356(1–2):333–344
73. Lu W et al (2008) The use of solid lipid nanoparticles to target a lipophilic molecule to the liver after intravenous administration to mice. Int J Biol Macromol 43(3):320–324
74. Ma Z et al (2000) New developments in particle characterization by laser diffraction: size and shape. Powder Technol 111(1–2):66–78
75. Manjunath K, Venkateswarlu V (2005) Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release 107(2):215–228
76. Martins S et al (2012) Multivariate design for the evaluation of lipid and surfactant composition effect for optimisation of lipid nanoparticles. Eur J Pharm Sci 45:613–623
77. McCauley JA, Brittain HG (1995) Thermal methods of analysis. In: Brittain HG (ed) Physical characterization of pharmaceutical solids. Marcel Dekker, New York, pp 224–250
78. McElhaney RN (1982) The use of differential scanning calorimetry and differential thermal analysis in studies of model and biological membranes. Chem Phys Lipids 30(2–3):229–259
79. Mishra B, Patel BB, Tiwari S (2010) Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery. Nanomedicine 6(1):9–24
80. Moghimi SM, Hunter AC, Murray JC (2001) Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 53(2):283–318
81. Mrsny RJ (2012) Perspective: oral drug delivery research in Europe. J Control Release 161:247–253
82. Mühlen AZ et al (1996) Atomic force microscopy studies of solid lipid nanoparticles. Pharm Res 13(9):1411–1416
83. Müller RH, Mäder K, Gohla S (2000) Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art. Eur J Pharm Biopharm 50(1):161–177
84. Müller RH et al (2008) Cyclosporine-loaded solid lipid nanoparticles (SLN®): drug–lipid physicochemical interactions and characterization of drug incorporation. Eur J Pharm Biopharm 68(3):535–544
85. Muller-Goymann CC (2004) Physicochemical characterization of colloidal drug delivery systems such as reverse micelles, vesicles, liquid crystals and nanoparticles for topical administration. Eur J Pharm Biopharm 58(2):343–356
86. Nassimi M et al (2010) A toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug delivery system for the lung. Eur J Pharm Biopharm 75(2):107–116
87. Neubert RHH (2011) Potentials of new nanocarriers for dermal and transdermal drug delivery. Eur J Pharm Biopharm 77(1):1–2
88. Noack A, Hause G, Mäder K (2012) Physicochemical characterization of curcuminoid-loaded solid lipid nanoparticles. Int J Pharm 423:440–451
89. Olbrich C et al (2001) Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA. J Control Release 77(3):345–355
90. Olbrich C, Kayser O, Müller RH (2002) Lipase degradation of Dynasan 114 and 116 solid lipid nanoparticles (SLN)—effect of surfactants, storage time and crystallinity. Int J Pharm 237(1–2):119–128
91. Pandey R, Khuller GK (2005) Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis 85(4):227–234
92. Patel PA, Patravale VB (2011) AmbiOnp: solid lipid nanoparticles of amphotericin B for oral administration. J Biomed Nanotechnol 7(5):632–639
93. Pedersen N et al (2006) Solid lipid nanoparticles can effectively bind DNA, streptavidin and biotinylated ligands. Eur J Pharm Biopharm 62(2):155–162
94. Petersen S et al (2011) The physical state of lipid nanoparticles influences their effect on in vitro cell viability. Eur J Pharm Biopharm 79(1):150–161
95. Quintanar-Guerrero D et al (1999) Pseudolatex preparation using a novel emulsion–diffusion process involving direct displacement of partially water-miscible solvents by distillation. Int J Pharm 188(2):155–164
96. Rahman Z, Zidan AS, Khan MA (2010) Non-destructive methods of characterization of risperidone solid lipid nanoparticles. Eur J Pharm Biopharm 76(1):127–137
97. Renliang X (2008) Progress in nanoparticles characterization: sizing and zeta potential measurement. Particuology 6(2):112–115
98. Rosen MJ (2004) Surfactants and interfacial phenomena, 3rd edn. Wiley, New Jersey
99. Sandri G et al (2010) Chitosan-associated SLN: in vitro and ex vivo characterization of cyclosporine A loaded ophthalmic systems. J Microencapsul 27(8):735–746
100. Sanna V, Caria G, Mariani A (2010) Effect of lipid nanoparticles containing fatty alcohols having different chain length on the ex vivo skin permeability of Econazole nitrate. Powder Technol 201(1):32–36
101. Sant S et al (2012) Microfabrication technologies for oral drug delivery. Adv Drug Deliv Rev 64:496–507
102. Sarmento B et al (2011) Effect of chitosan coating in overcoming the phagocytosis of insulin loaded solid lipid nanoparticles by mononuclear phagocyte system. Carbohydr Polym 84(3):919–925
103. Schubert MA, Muller-Goymann CC (2005) Characterisation of surface-modified solid lipid nanoparticles (SLN): influence of lecithin and nonionic emulsifier. Eur J Pharm Biopharm 61(1–2):77–86
104. Schubert MA, Harms M, Müller-Goymann CC (2006) Structural investigations on lipid nanoparticles containing high amounts of lecithin. Eur J Pharm Sci 27(2–3):226–236
105. Severino P et al (2011) Polymorphism, crystallinity and hydrophilic–lipophilic balance of stearic acid and stearic acid–capric/caprylic triglyceride matrices for production of stable nanoparticles. Colloids Surf B: Biointerfaces 86(1):125–130
106. Severino P et al (2012) Current state-of-art and new trends on lipid nanoparticles (SLN and NLC) for oral drug delivery. J Drug Deliv 2012:750–891
107. Shahgaldian P et al (2003) AFM imaging of calixarene based solid lipid nanoparticles in gel matrices. Eur J Pharm Biopharm 55(1):107–113
108. Sinha VR et al (2011) Solid lipid nanoparticles (SLN´s)—trends and implications in drug targeting. Int J Adv Pharm Sci 1:212–238
109. Sivaramakrishnan R et al (2004) Glucocorticoid entrapment into lipid carriers—characterization by parelectric spectroscopy and influence on dermal uptake. J Control Release 97(3):493–502
110. Sjöström B, Bergenstahl B (1992) Preparation of submicron drug particles in lecithin-stabilized o/w emulsions I. Model studies of the precipitation of cholestreryl acetate. Int J Pharm 88:53–62
111. Souto EB, Doktorovova S (2009) Chapter 6—solid lipid nanoparticle formulations pharmacokinetic and biopharmaceutical aspects in drug delivery. Methods Enzymol 464:105–129
112. Souto EB, Müller RH (2005) The use of SLN® and NLC® as topical particulate carriers for imidazole antifungal agents. Die Pharmazie 61(5):431–437
113. Souto EB, Muller RH (2006) Investigation of the factors influencing the incorporation of clotrimazole in SLN and NLC prepared by hot high-pressure homogenization. J Microencapsul 23:377–388
114. Souto EB, Müller RH (2007) Lipid nanoparticles (SLN and NLC) for drug delivery. In: Domb J et al (eds) Nanoparticles for pharmaceutical applications. American Scientific Publishers, Los Angeles, CA, pp 103–122
115. Souto EB, Muller RH (2010) Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes. Handb Exp Pharmacol 197:115–141
116. Souto EB, Muller RH (2011) Solid lipid nanoparticles and nanostructures lipid carriers—lipid nanoparticles for medicals and pharmaceuticals. Encyclopedia Nanosci Nanotechnol 23:313–328
117. Souto EB et al (2004a) Comparative study between the viscoelastic behaviors of different lipid nanoparticle formulations. J Cosmet Sci 55:463–471
118. Souto EB et al (2004b) Evaluation of the physical stability of SLN and NLC before and after incorporation into hydrogel formulations. Eur J Pharm Biopharm 58(1):83–90
119. Souto EB, Mehnert W, Müller RH (2006) Polymorphic behaviour of Compritol 888 ATO as bulk lipid and as SLN and NLC. J Microencapsul 23(4):417–433
120. Souto EB et al (2011a) Lipid-based nanocarriers for cutaneous administration of pharmaceutics. Encyclopedia Nanosci Nanotechnol 15:479–491
121. Souto EB, Doktorovova S, Boonme P (2011b) Lipid-based colloidal systems (nanoparticles, microemulsions) for drug delivery to the skin: materials and end-product formulations. J Drug Del Sci Tech 21(1):43–54
122. Sznitowska M et al (2001) Bioavailability of diazepam from aqueous-organic solution, submicron emulsion and solid lipid nanoparticles after rectal administration in rabbits. Eur J Pharm Biopharm 52(2):159–163
123. Tabatt K et al (2004) Transfection with different colloidal systems: comparison of solid lipid nanoparticles and liposomes. J Control Release 97(2):321–332
124. Venishetty VK et al (2012) Design and evaluation of polymer coated carvedilol loaded solid lipid nanoparticles to improve the oral bioavailability: a novel strategy to avoid intraduodenal administration. Colloids Surf B: Biointerfaces 95:1–9
125. Videira MA et al (2002) Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J Drug Target 10(8):607–613
126. Videira M, Almeida AJ, Fabra À (2012) Preclinical evaluation of a pulmonary delivered paclitaxel-loaded lipid nanocarrier antitumor effect. Nanomed Nanotechnol Biol Med 8:1208–1215
127. Vieira V et al (2012) Characterization of the physicochemical performance of nimesulide-loaded lipid nanoparticulates. In: Third scientific meeting of the institute for biotechnology and bioengineering. Lisbon, Portugal
128. Vighi E et al (2007) Re-dispersible cationic solid lipid nanoparticles (SLNs) freeze-dried without cryoprotectors: characterization and ability to bind the pEGFP-plasmid. Eur J Pharm Biopharm 67(2):320–328
129. Vighi E et al (2010) PDNA condensation capacity and in vitro gene delivery properties of cationic solid lipid nanoparticles. Int J Pharm 389(1–2):254–261
130. Westesen K, Siekmann B, Koch MHJ (1993) Investigations on the physical state of lipid nanoparticles by synchrotron radiation X-ray diffraction. Int J Pharm 93(1–3):189–199
131. Westesen K, Bunjes H, Koch MHJ (1997) Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J Control Release 48(2–3):223–236
132. Wiechers J, Souto EB (2010) Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) as novel delivery systems for cosmetic actives. Part I. Cosmet Toiletries 10:22–30
133. Wissing SA, Kayser O, Muller RH (2004) Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 56(9):1257–1272
134. Yang W, Peters JI, Williams RO III (2008) Inhaled nanoparticles—a current review. Int J Pharm 356(1–2):239–247
135. Yoo J-W, Doshi N, Mitragotri S (2011) Adaptive micro and nanoparticles: temporal control over carrier properties to facilitate drug delivery. Adv Drug Deliv Rev 63(14–15):1247–1256
136. Zhang Q et al (2000) Studies on the cyclosporin A loaded stearic acid nanoparticles. Int J Pharm 200(2):153–159
137. Zhang S-H et al (2008) Preparation of solid lipid nanoparticles in co-flowing microchannels. Chem Eng J 144(2):324–328